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NC-ND license (http://creativecommoPediatric non-cystic fibrosis (CF) bronchiectasis is characterized by endobronchial suppuration,
airway neutrophilic inflammation and poor mucus clearance and is associated with persistent
productive cough due to recurrent airway infections. Most recommendations are based on
expert opinion or extrapolated from CF practice. The present narrative review aims to address
some issues on the management of children or adolescents with non CF-bronchiectasis that still
require attention, and analyze what available literature offers to reply to open questions. We
focused on the potential offered by technological advances on lung disease assessment
through novel chest imaging techniques and new or old pulmonary function tests. We also sum-
marized the main novelties in the disease prevention and treatment. Finally, a novel diagnostic
algorithm is proposed, that might help physicians in the daily clinical decision-making process.
Future directions for research on pediatric non-CF bronchiectasis should include larger study
populations and longer prospective clinical trials, as well as new clinical and laboratory end-
points to determine the underlying mechanisms of lung disease progression and support the
role of new and existing treatments.
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+ MODEL1. Introduction
Three clinical entities, associated with endobronchial sup-
puration, neutrophilic inflammation and poor mucus
clearance, have been merged under the spectrum of pe-
diatric suppurative lung disorders, i.e., protracted bacte-
rial bronchitis (PBB), chronic suppurative lung disease
(CSLD) and bronchiectasis.1 While PBB is a syndrome with
isolated persistent wet cough resolving after 2e4 weeks of
oral antibiotics and with normal chest imaging (except for
occasional peribronchial thickening), bronchiectasis in
childhood is defined as the presence of persistent or
recurrent (>3) episodes of chronic (>4 weeks) productive
cough, sometimes with coarse crackles and digital club-
bing, associated with the chest computed tomography (CT)
finding of a ratio between the inner airway and the outer
vessel diameter 0.80.1 In between PBB and bronchiec-
tasis, there is CSLD, which defines patients with clinical
symptoms of bronchiectasis without its radiographic fea-
tures.1 As etiology and clinical features of bronchiectasis
and CSLD largely overlap, the conditions have been
frequently referred to simply as CSLD, yet the absence of
CT abnormalities makes a crucial difference.
The global burden of pediatric bronchiectasis is un-
known, although extrapolation of published data suggests
that prevalence ranges from 0.2e735 cases per 100 000
children.2 Indeed, heterogeneity of definitions, limited
access to diagnostic technology in some areas, and lack of
epidemiologic data from developing countries make a pre-
cise assessment of prevalence unreliable.3 What is clear is
that low-income populations have a higher incidence of
bronchiectasis, generally of infectious origin, with early
severe manifestations particularly amongst Australian, Pa-
cific Islands and Alaskan native people.2 In high-income
countries a major cause is cystic fibrosis (CF), whereas
within non-CF conditions epidemiologic data are less
consolidated. Although reported prevalence is affected by
the local diagnostic facilities, primary immune deficiencies
(PID), chronic/recurrent aspiration, postinfectious entities,
primary ciliary dyskinesia (PCD) and airways malformations
represent the most common causes everywhere.2,4e8 Un-
deniably, a relevant proportion of cases are probably clas-
sified as idiopathic because of insufficient awareness of the
underlying etiology and/or limited availability of diagnostic
resources (for example, those for ciliary motility and
structure defects). Should this be confirmed, the preva-
lence of the disorder could significantly change.
Management of non-CF bronchiectasis has long been
based on expert opinion or derived from CF. However, in
the last decade some recommendations on pediatric non-CF
bronchiectasis or specific disorders were published.4e6
These generally focus on diagnostic approach, clinical
monitoring and treatment for stable disease and exacer-
bations. Nevertheless, issues such as clinical applicability
of biomarkers, development of decision-making algorithms,
quality of life (QoL) evaluation, emerging lung function or
structure assessment technologies, and therapeutic chal-
lenges remain poorly addressed, leaving a number of
questions unanswered.
In the present narrative review we focus on some
“neglected” aspects and analyze what available literaturePlease cite this article as: Poeta M et al., Non-cystic fibrosis bronchiec
Pediatrics and Neonatology, https://doi.org/10.1016/j.pedneo.2019.0offers to reply to open questions. Furthermore, we present
an algorithm to help clinicians in moving from the initial
diagnosis to the identification of the underlying etiology.2. Old and new biomarkers
Relevance of biomarkers is crucial in clinical practice for
screening, early diagnosis or disease monitoring, and in
research as outcome measures. Blood measurements may
not reflect what happens in the airways, so lung biomarkers
are usually detected through bronchoalveolar lavage (BAL).
Biofilms produced by respiratory pathogens were isolated in
BAL from non-CF bronchiectasis children even when BAL-
defined infection was absent.9 Nevertheless, the need for
general sedation and the potential risks of BAL limit its use,
particularly in pediatric settings where a long-term follow-
up is required.
Collection of exhaled breath condensate (EBC) provides
a non-invasive method to assess lower airway biomarkers
that is more suitable for children than BAL. In CF and non-
CF bronchiectasis, EBC contains high levels of matrix met-
alloproteases, which correlate with worse spirometry and
high resolution CT (HRCT).10 Interestingly, the application
of metabolomics to EBC also showed how nuclear magnetic
resonance spectroscopy discriminates healthy subjects
from CF and PCD patients.11 In EBC from PCD children, 8-
isoprostane, a marker of oxidative stress, is increased,12
and nitric oxide (NO) metabolites are similar to controls,
despite reduced nasal NO (nNO).13 It is hoped that further
studies will clarify the role of EBC metabolic profiling in the
characterization of bronchiectasis with different etiology.
Induced sputum is a safe, non-invasive tool for sampling
secretions from the lower airways particularly in non-
expectorating young children.14 Unfortunately, it was
rarely applied to pediatric non-CF bronchiectasis and
further studies should be encouraged, especially when BAL
is not feasible.
In the field of non-invasive biomarkers a relevant role
has been gained by NO.15 Measurement includes fractional
exhaled NO (FeNO) and the less widespread nNO. FeNO
analysis is well validated in the assessment of asthma
control, but its application to other conditions is less
studied. Similarly, despite a growing body of evidence
supporting the utility of nNO in the diagnostic work-up of
several disorders, current literature indicates its major
application in PCD screening.4 In PCD, nNO is markedly
reduced for unclear reasons but may be normal in cases
with subtle beating abnormalities of cilia.5 Indeed, low nNO
levels are also permissive for PCD airway colonization by
non-typeable Haemophilus influenzae (NTHi).16 An official
guideline has concluded that nNO helps to address further
testing or support the diagnosis of patients with atypical
phenotypes and/or normal ciliary ultrastructure, but a
definite diagnosis of PCD cannot be based on nNO alone.43. Functional and structural lung disease
assessment
Unlike other organs which can be easily monitored through
imaging or function tests, e.g., kidney or liver, lung is fartasis in children and adolescents: Neglected and emerging issues,
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and monitor lung function and structure, the development
of reliable non-invasive tools represents a priority in pedi-
atrics and a remaining challenge.
3.1. Lung function
Wide diffusion, low cost and non-invasiveness makes
spirometry a valuable tool for assessing efficacy of treat-
ment and monitoring pulmonary deterioration.17,18 Never-
theless, spirometry fails to detect early disease and
peripheral airways changes of some conditions.19 There is
also increasing recognition that in CF and non-CF bronchi-
ectasis HRCT lung changes may occur despite normal
spirometry.20 Spirometry is also limited by the need of pa-
tient’s cooperation. Indeed, virtually no data are available
in non-CF preschoolers, though PCD abnormalities are
evident in infancy.17 The static lung volumes determination
may be useful as well, but the limited diffusion of such a
technique and an even higher need for patients’ coopera-
tion compared to spirometry strongly affect the application
of plethysmography in children. A study of 17 children with
postinfectious bronchiectasis undergoing the multiple he-
lium dilution technique demonstrated increased residual
volume and residual volume/total lung capacity ratio.21
Lung clearance index (LCI), a non-effort-dependent
technique also applicable to young children, is increased
in many conditions, such as CF and asthma, and increasing
evidence supports its role as an earlier marker of distal
airway impairment compared to spirometry.22 Data in adult
bronchiectasis are less conclusive as one study excluded
that LCI is useful for short-term assessment of the response
to antibiotics.23 Evidence in children mainly derives from
PCD literature which showed that LCI is very sensitive in
detecting structural and functional abnormalities even in
the presence of normal FEV1.
24e26 Conversely, a compara-
tive study of LCI, HRCT and spirometry concluded that LCI is
not a sensitive test of airway disease in advanced PCD as it
does not correlate with HRCT.27 Because of these contro-
versial results, LCI is not listed in the diagnostic work-up,
but more studies should be encouraged. Finally, fraction
of end-expiratory oxygen (FEO2) measured by a fast-
response analyzer connected to a pneumotachometer was
recently proposed as a non-invasive test to evaluate O2
tension of distal airways.28 The FEO2 in CF was found to be
significantly lower than in PCD, possibly given the thinner
PCD airways secretions compared to CF mucus plugs, sup-
porting a potential application of this procedure for
screening PCD in cases with bronchiectasis.
3.2. Lung structure
An accurate assessment of lung structure is crucial for
identifying bronchiectasis,1 but CT is criticized for its
ionizing radiation burden. Alternative techniques have
been investigated and an increasing body of literature has
become available particularly for chest magnetic resonance
imaging (MRI) and, to a lesser extent, for electric imped-
ance tomography (EIT).
MRI has been repeatedly proposed as reliable radiation-
free technique in several disorders and the diffusion ofPlease cite this article as: Poeta M et al., Non-cystic fibrosis bronchiec
Pediatrics and Neonatology, https://doi.org/10.1016/j.pedneo.2019.0high-field 3-0-T MRI has partially overcome technical
problems such as long acquisition times, need for patient
cooperation, respiratory and cardiac motion artifacts, and
low signal-to-noise ratio due to low proton density of the
lung.29 Good agreement between chest high-field MRI and
HRCT and significant correlation with pulmonary function
have been found, with good-to-excellent sensitivity and
specificity.30 Moreover, functional MRI has been proposed to
assess lung perfusion (i.e., the dynamic contrast-enhanced
MRI with intravenous gadolinium) or lung mechanics (by a
spirometer-controlled technique), or lung ventilation with
inhaled hyperpolarized gases, or to evaluate both perfusion
and ventilation without contrast media (by the Fourier
decomposition procedure),29 but studies of pediatric non-
CF bronchiectasis are few. A recent study of functional
MRI in PCD children and adults has supported the use of
chest MRI sequences without the need for contrast agents
or breathing manoeuvers.31
EIT is a strongly function-oriented radiations-free imag-
ing modality whose applications in pediatrics are raising
growing interest,32 but robust studies in non-CF bronchi-
ectasis are lacking. However, future EIT application in pe-
diatric respiratory medicine might provide valuable
information on chest regional changes.4. Quality of life assessment tools
Monitoring chronic respiratory diseases has traditionally
focused on periodical assessment of clinical, functional and
imaging outcomes.1 However, these parameters are inad-
equate to evaluate how disease impacts on children’s
everyday life.33 Therefore, the role of QoL, particularly
health-related QoL (HRQoL), has increasingly gained rele-
vance in the management of pediatric disorders. This
determined an effort in standardizing HRQoL evaluation
tools; hence disease-specific questionnaires for pediatric
patients or their parents were developed.34,35 QoL is
strongly affected by the respiratory condition both in terms
of physical and mental functioning.33 In non-CF bronchi-
ectasis, parental distress is high, with mental health worse
than in CF parents, which is probably due to less intensive
interaction with healthcare professionals.36
Most studies assessing QoL in non-CF bronchiectasis have
used tools originally designed for chronic cough, which,
although informative, may be incomplete.33 Recently, the
QoL Questionnaire-Bronchiectasis was developed as the
first specific tool for non-CF bronchiectasis with good
reproducibility and reliability in adults.34 Nevertheless, as
the heterogeneity of non-CF bronchiectasis mitigates
against the development of a comprehensive patient-
reported outcome measure, QoL questionnaires have been
recently validated for specific conditions.35 Particularly,
whereas tools of QoL in children with bronchiectasis sec-
ondary to PID or chronic aspiration are lacking, a HRQoL
measure was developed for PCD children that takes into
account general aspects common to chronic lung disorders
and specific issues of this population (i.e., sinus/ear dis-
ease).37 Despite these advances, evidence of QoL in chil-
dren is still limited. Further application of new tools
designed for specific diseases will lead towards a better
assessment of QoL.tasis in children and adolescents: Neglected and emerging issues,
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Table 1 Summary of pediatric trials on airway clearance
techniques or pulmonary rehabilitation in non-cystic fibrosis
bronchiectasis.
Intervention Main results Comments
Positive expiratory
pressure mask44
Significant
improvement of
pre- versus post-
treatment regional
lung ventilation.
No change of pre-
versus post-
treatment FEV1.
8-week trial in
6 children
No comparison
group not
undergoing
airway
clearance
techniques.
Supervised
physiotherapy45
Significant
thoracic gas
volume decrease
and FEV1
improvement
versus
unsupervised
controls.
1-month trial in
24 children.
No comparison
group not
undergoing
airway
clearance
techniques.
Inspiratory-threshold
loading device and
cough training46
Significantly
improved
pulmonary
function and
respiratory muscle
strength in treated
versus untreated
subjects.
8-week trial
(abstract).
Postural drainage,
percussion and
vibration versus
high-frequency
chest wall
oscillation47
Significantly
improved
pulmonary
function, no
desaturation and
no differences
between methods.
Both methods
efficient, chest
wall oscillation
more comfortable.
Controlled
randomized
crossover study
of 2 methods in
24 children
with primary
ciliary
dyskinesia.
Efficiency and
comfort
measured
subjectively.
Short study
period.
4 M. Poeta et al
+ MODEL5. Therapeutic strategies: areas of certainty
and new challenges
Disappointingly, most of the pediatric literature on treat-
ment of non-CF bronchiectasis is composed of reviews with
recommendations1,5 or is extrapolated from CF.38 Never-
theless, despite the lack of controlled clinical trials, few
guidelines have addressed the treatment of children.6,39,40
At any age, the primary goals of bronchiectasis manage-
ment are to prevent premature respiratory decline, to
suppress airway infections minimizing exacerbations, to
reduce morbidity and mortality, and to improve HRQoL.1
Core prescriptions include daily airway clearance tech-
niques (ACT) and pulmonary rehabilitation programs as well
as measures of infection control and prevention.
5.1. Airway clearance techniques and pulmonary
rehabilitation programs
Pulmonary rehabilitation programs and ACTs including
manual chest physiotherapy with percussion and vibration,
postural drainage, autogenic drainage, active cycle
breathing, positive expiratory pressure (PEP) devices and
mechanical cough assist have been exhaustively described
in CF and in adult disorders.41e43 Current international
guidelines recommend ACT as part of routine management
in non-CF bronchiectasis,6,39,40 even though the evidence
basis is sparse.41e43 In the last two decades few pediatric
trials have been published,44e47 but the small sample size,
the short study periods and, at least for some, the absence
of a comparison group make it difficult to claim superiority
of a specific mode (Table 1). As aerobic fitness is a
cardiorespiratory prognostic measure, exercise would be
also beneficial, but pediatric publications in non-CF bron-
chiectasis are limited.21,48,49 Actually, training and
frequent revision by a respiratory therapist are mandatory
to reach the goal of mobilizing secretions and interrupt the
vicious cycle of inflammation and infection, and a person-
alized plan including clear written advice should be tailored
to individual needs. Despite the limited number of
evidence-based studies, some key practice points should be
kept in mind and recommended (Table 2). Finally, as
adherence can be suboptimal, novel approaches to mea-
sures adherence in children and adolescents should be
encouraged (Clinical Trial: NCT02906826).
5.2. Pharmacological treatment
The pathogens colonization of lower airways is associated
with more severe and frequent exacerbations and fuels the
vicious cycle of infection > inflammation > lung damage
that further increases bacterial growth.1 Antibiotics reduce
airway bacterial load and consequently should interrupt the
vicious cycle. Adult and pediatric guidelines recommend
oral or intravenous antibiotic course for at least 10e14
days, prescribed on the basis of known or suspected path-
ogens colonization.6,39,40 Macrolides have been used in a
number of pediatric short- or long-term randomized
controlled trials (RCT) of non-CF bronchiectasis (Table
3).50e53 The non-inferiority of azithromycin versus
amoxicillin-clavulanate was shown in a recent RCT,Please cite this article as: Poeta M et al., Non-cystic fibrosis bronchiec
Pediatrics and Neonatology, https://doi.org/10.1016/j.pedneo.2019.0suggesting that macrolides may be alternatively used for
treating non-severe exacerbations in children with non-CF
bronchiectasis who have penicillin hypersensitivity or poor
adherence to twice-daily antibiotic administration.54
Guidelines suggest prescription of inhaled antibiotics in
patients with frequent exacerbations and Pseudomonas
aeruginosa infections, or when macrolides are contra-
indicated.6,39,40 Regrettably, pediatric studies evaluating
inhaled antibiotics (aminoglycosides; colistin; aztreonam),
or bronchodilators, or hyperosmolar agents (hypertonic
saline or mannitol) are lacking. Also, inhaled mucolytics
such as recombinant human DNase have been evaluated intasis in children and adolescents: Neglected and emerging issues,
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Table 2 Key practice points for pulmonary rehabilitation
programs and airways clearance techniques in children and
adolescents with non-cystic fibrosis bronchiectasis.
 Consider the patient age and the etiology of the disorder
 Individualize the treatment
 Educate the patient and the family, also with clear writ-
ten advice on actions to take if symptoms deteriorate
 Be ready to change the treatment, if needed
 Develop a scheduled written follow-up plan
 Set a cluster of goals to be reached, e.g., improvement of
spirometry or exercise test
 Start as soon as possible
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+ MODELvery small case series or anecdotal reports.55 Apparently,
there is no role for oral or inhaled glucocorticoids in bron-
chiectasis, other than the treatment of atopic conditions orTable 3 Summary of randomized controlled trials with
different macrolides in pediatric non-cystic fibrosis
bronchiectasis.
Main results Comments
Roxithromycin50 No change in FEV1,
airway
responsiveness,
sputum purulence
and leucocytes.
Double-blind
placebo
randomized
controlled trial of
twice-daily dose
treatment for 12
weeks.
Claritromycin51 Significant decrease
in cytokine,
neutrophils and
sputum volume.
Significant increase of
sputum macrophage
ratios. No significant
change in FEV1.
Randomized
controlled trial of
12 weeks
treatment.
Azithromycin52 Reduced rate of
exacerbations and
improved weight-for-
age z-score.
Increased
macrolide
resistance in
nasopharynx
pathogens in a
randomized
controlled trial of
once-weekly dose
treatment for 12
e24 months.
Erithromycin53 No significant change
in the number of
exacerbations
No improvement in
lung function
No impact on the
levels of cytokines.
Double-blind
placebo
randomized
controlled trial
assessing efficacy
of once-daily dose
treatment for 52
weeks to children
with HIV-related
bronchiectasis.
Please cite this article as: Poeta M et al., Non-cystic fibrosis bronchiec
Pediatrics and Neonatology, https://doi.org/10.1016/j.pedneo.2019.0of allergic aspergillosis.1 Despite this, most of these agents
continue to be used in the daily practice, and this is a
stimulus to promoting further research.
A relevant question about treatment of pediatric non-CF
bronchiectasis is what the future holds. A clinical trial of
azithromycin in PCD children and adults is under way, and
results are awaited to clarify whether maintenance mac-
rolides affect lung function and symptoms.56 Another PCD
study has recently found that in epithelial cells co-cultured
with NTHi the association of azithromycin plus a cephalo-
sporin-30-diazeniumdiolate NO donor prodrug significantly
decreased NTHi viability, suggesting that exogenous NO
plus antibiotics might be a novel therapeutic approach.16 As
airways colonization may be complicated by bacterial bio-
film, a study of non-CF adults showing superior antimicro-
bial efficacy of inhaled antibiotic nanoparticles compared
to inhaled native antibiotics opens the door for innovative
biomedical treatment of biofilm infections.57
5.3. Surgical strategies
Resection of the affected area also by video-assisted
thoracoscopy is safe at any age. A recent meta-analysis
showed benefits of lung resection in non-CF bronchiectasis
with low mortality, acceptable morbidity and significant
improvements in symptoms.58 Indeed, many surgical
studies have important limitations including the efficacy
assessment through only roughly defined clinical features,
the absence of a control group in most of them, and the
involvement of mixed populations of children and adults.
Interestingly, approximately 60% of the studies have been
conducted in Middle Eastern populations (especially, Turkey
and Iran) who, apparently, are not investigated for genetic
disorders other than CF.58 Therefore, we cannot exclude
that in developing countries the higher frequency of sur-
gery is due to inadequate or delayed start of medical
treatment or to a late/missed diagnosis of specific disor-
ders. Indeed, considering the high frequency of consan-
guinity in this geographic area, many bronchiectasis cases
defined as “postinfectious” may actually hide an unidenti-
fied genetic etiology due to lack of local availability of
certain investigations (for instance, cilia microscopy,
motility or genetics; immunological studies).3 Surgery in-
dications include failure of conservative treatment, recur-
rent hemoptysis or destroyed lung parenchyma. Overall,
although symptoms may decrease or disappear after
resection, surgical treatment remains controversial and
high caution should be exercised concerning the decision,
especially in children. A priority remains that conservative
strategies should be started as soon as possible, avoiding
unnecessary surgery, or at least restricting its indications to
patients who fail to improve after medical treatment.
Finally, transplantation is also a well-established treatment
for end-stage bronchiectasis, but there are no reports in
non-CF pediatric bronchiectasis.
5.4. Prevention of infections
Seasonal influenza and pneumococcal vaccines are recom-
mended for people with bronchiectasis.1,6 Interestingly, a
recent RCT of children with PBB, CSLD or non-CFtasis in children and adolescents: Neglected and emerging issues,
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Figure 1 Diagnostic approach to children with clinical features and radiological diagnosis of bronchiectasis.
CFTR, cystic fibrosis transmembrane conductance regulator; GERD, gastro-esophageal reflux disease; TEF, trachea-esophageal
fistula; GI, gastrointestinal; PPD, purified protein derivative; PCR, polymerase chain reaction; BAL, bronchoalveolar lavage; MRI,
magnetic resonance imaging; CT, computed tomography.
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pneumococcal-H. influenzae protein D conjugate vaccine
(PHiD-CV) in terms of reduction in antibiotic courses, res-
piratory symptoms and hospitalized exacerbations and sig-
nificant immune response also towards NTHi.59
Furthermore, the effectiveness towards NTHi has been
microbiologically confirmed on samples of BAL fluids and
nasopharyngeal swabs of children with chronic cough who
received a primary course of two PHiD-CV doses compared
to 7- or 13-valent pneumococcal vaccine.60 In pediatric
non-CF bronchiectasis there are no studies on P. aeruginosa
vaccines, but these might have a role in the difficult air-
ways infection control.
6. Diagnostic algorithm
In most cases, managing children with non-CF bronchiec-
tasis means dealing with rare conditions that require
specialist referral to provide standardized approaches.
Nevertheless, before expert consultation, patients are
managed by primary care health professionals who are
seldom trained and confident enough to assess the disease
correctly. In this scenario, structured pathways for clinical
decision-making have been published, including diagnostic
procedures and even indications or timing for specialist
referral of a number of specific conditions lying under the
umbrella of pediatric non-CF bronchiectasis. Actually, a
more comprehensive algorithm aembracing non-CF bron-
chiectasis as a clinical syndrome and orientating the diag-
nostic approach towards specific etiologies is lacking. We
propose a diagnostic pathway to guide clinicians towardsPlease cite this article as: Poeta M et al., Non-cystic fibrosis bronchiec
Pediatrics and Neonatology, https://doi.org/10.1016/j.pedneo.2019.0the identification of the specific etiology of the disorder
(Fig. 1). When facing a child or adolescent with clinical
features and confirmed HRCT evidence of bronchiectasis,
we first suggest exclusion of the genetic disorders that
primarily involve the respiratory tract and the host’s de-
fense against pathogens, i.e., CF, PCD, and primary im-
mune defects. Once these have been excluded, we propose
a cluster of additional diagnostic tests to investigate
bronchiectasis and suggest how to manage cases when the
work-up is inconclusive. As with all algorithms, it does not
substitute clinical judgment, especially considering
phenotypical heterogeneity of non-CF bronchiectasis, but it
may provide a systematic approach to it.
7. Conclusions
It has already become widely accepted that the manage-
ment of pediatric non-CF bronchiectasis should no longer
be dependent upon extrapolating from CF or adult disorders
experience. A lot still needs to be done, but we trust the
path is set. For instance, as mutations underlying specific
disorders, such as PID or PCD, are increasingly identi-
fied,61,62 the possibility of individualized treatment pri-
marily including gene therapy is rising.
Regrettably, non-CF bronchiectasis is still understudied
in children, and it still suffers neglect in some areas and
also relevant emerging issues need to be addressed. Over-
all, diagnostic tests in pediatric pulmonology require high
expertise. To overcome difficulties in the procedure and
interpretation of results in non-CF bronchiectasis, novel
networks such as ERN Lung63 and BEAT-PCD (COST Action BMtasis in children and adolescents: Neglected and emerging issues,
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+ MODEL1407)64 have been developed to improve access to diagnosis
and treatment of non-CF bronchiectasis and PCD,
respectively.
Future research should include larger study populations
and RCTs, as well as new clinical and laboratory endpoints,
in order to determine the underlying mechanisms of lung
disease progression and identify the predictors of exacer-
bations, to investigate, whenever possible, the correlations
of genotype and phenotype and to support the role of new
preventive and therapeutic strategies.
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